Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Deciphering Thrombosis Risk in Vexas Syndrome Patients through Thrombin Generation Assay Andthromboelastography

Mael Heiblig, Christophe Nougier, Jamilloux Yvan, Pierre Sujobert, Yesim Dargaud

Blood (2023) 142 (Supplement 1): 1280.

https://doi.org/10.1182/blood-2023-185809

Published: 2023

Journal Articles

Genotype-Phenotype Mapping Via Single-Cell Multi-Omics Identifies Therapeutic Vulnerabilities in Vexas Syndrome

Saravanan Ganesan, Rebecca Murray, Jesus Sotelo, Theo Botella, Elliot Eton, Nada Chraiki, Carolyne Croizier, Franco Izzo, Catherine Potenski, Benjamin Terrier, Mael Heiblig, Pierre Sujobert, Olivier Kosmider, David B Beck, Dan A. Landau

Blood (2023) 142 (Supplement 1): 813.

https://doi.org/10.1182/blood-2023-184313

Published: 2023

Journal Articles

Deep Learning Based Blood Abnormalities Detection As a Tool for Vexas Syndrome Screening

Blood (2023) 142 (Supplement 1): 3648.

https://doi.org/10.1182/blood-2023-186874

Published: 2023

Journal Articles

BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1

Blood (2023) 141 (10): 1209–1220.

https://doi.org/10.1182/blood.2022016943

Published: 2023

Includes: Multimedia, Supplemental data

Journal Articles

Correlation of Clonal Hematopoiesis in Vexas Syndrome with Immunophenotype Alterations in CD34+ HSPCs (Hematopoietic Stem Progenitors Cells): Multiparametric Flow Cytometry Heterogeneity in CD34+CD38- Stem Cells Fraction and Upregulation of CD90 Thy-1 By Unsupervised Strategy Using PCA, Tsnee and Flowsom

Adriana Plesa, Joris Gutrin, Christophe Roumier, Sandrine Hayette, Isabelle Tigaud, Sarah Huet, Delphine Manzoni, Florent Dumezy, Fiorenza Barraco, Herve Ghesquieres, Claude Preudhomme, Pierre Sujobert, Mael Heiblig

Blood (2022) 140 (Supplement 1): 4086–4087.

https://doi.org/10.1182/blood-2022-169959

Published: 2022

Journal Articles

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Blood (2022) 140 (Supplement 1): 9668–9669.

https://doi.org/10.1182/blood-2022-159928

Published: 2022

Journal Articles

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

Blood (2022) 140 (8): 927–931.

https://doi.org/10.1182/blood.2022016642

Published: 2022

Includes: Supplemental data

Journal Articles

Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study

Blood (2021) 138 (Supplement 1): 2608.

https://doi.org/10.1182/blood-2021-150394

Published: 2021

Journal Articles

Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas

Blood (2021) 138 (Supplement 1): 809.

https://doi.org/10.1182/blood-2021-150034

Published: 2021

Journal Articles

Therapeutic options in VEXAS syndrome: insights from a retrospective series

Estelle Bourbon, Maël Heiblig, Mathieu Gerfaud Valentin, Thomas Barba, Cécile-Audrey Durel, Jean Christophe Lega, Fiorenza Barraco, Pascal Sève, Yvan Jamilloux, Pierre Sujobert

Blood (2021) 137 (26): 3682–3684.

https://doi.org/10.1182/blood.2020010177

Published: 2021

Includes: Supplemental data

Journal Articles

A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia

Blood (2021) 137 (4): 524–532.

https://doi.org/10.1182/blood.2020005524

Published: 2021

Includes: Supplemental data

Journal Articles

Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

Christiane Copie Bergman, MDPhD, Elodie Bohers, PhD, Peggy Dartigues-Cuillères, MD, Pierre-Julien Viailly, Philippe Ruminy, PhD, Vinciane Marchand, Marie-Helene Delfau-Larue, Corinne Haioun, MDPhD, Cyrielle Robe, Elsa Poullot, MD, Steven Le Gouill, MD PhD, Yannick Le Bris, PharmD, Céline Bossard, MD, Anne Moreau, MD, Vincent Ribrag, MD, Valérie Camara-clayette, PhD, Cyril Quivoron, PhD, Gilles Salles, MDPhD, Sophie Cotteret, MD PhD, Pierre Sujobert, MD PhD, Alexandra Traverse-Glehen, MD PhD, Claire Mauduit, Pascaline Etancelin, Sarah Huet, Liana Veresezan, MD, Krimo Bouabdallah, MD, Marie Parrens, MD, Audrey Gros, PhD, Samuel Amintas, David Sibon, MD PhD, Ludovic Lhermitte, MD PhD, Thomas Steimle, Sophie Kaltenbach, Bettina Fabiani, MD, Camille Laurent, MD PhD, Barbara Burroni, Laurent Martin, MD PhD, Thierry Jo Molina, MDPhD, Lysa LYSARC study group, Fabrice Jardin, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141953

Published: 2020

Journal Articles

Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141890

Published: 2020

Journal Articles

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

Blood (2019) 134 (Supplement_1): 3021.

https://doi.org/10.1182/blood-2019-130907

Published: 2019

Journal Articles

PKR-like Endoplasmic Reticulum Kinase Mediates Apoptosis Induced By Pharmacological AMP-Activated Protein Kinase Activation in Acute Myeloid Leukemia

Laury Poulain, PhD, Adrien Grenier, MD PhD, Johanna Mondesir, MD, Arnaud Jacquel, PhD, Claudie Bosc, Lucille Stuani, PhD, Rudy Birsen, MD, Sarah Mouche, Justine Decroocq, MD, Fetta Mazed, PhD, Benoit Viollet, PhD, Patrick Auberger, PhD, Pierre Sujobert, MD PhD, Didier Bouscary, MD PhD, Jean-Emmanuel Sarry, PhD, Jerome Tamburini, MD PhD

Blood (2019) 134 (Supplement_1): 2552.

https://doi.org/10.1182/blood-2019-123364

Published: 2019

Journal Articles

Integrating ELN Criteria and a 'Knowledge Bank' Approach to Guide Allogeneic Stem Cell Transplantation (SCT) Indication in Younger Adults with Acute Myeloid Leukemia (AML): An Acute Leukemia French Association Study

Blood (2019) 134 (Supplement_1): 1423.

https://doi.org/10.1182/blood-2019-122468

Published: 2019

Journal Articles

A French Multicentric Prospective Cohort of 6000 Patients with Integrative Epidemiological, Clinical, Biological and Treatment Data to Improve Knowledge on Outcome of Lymphoma Patients: Pilot Phase Results of the Real World Data in Lymphoma and Survival in Adults (REALYSA) Study

Herve Ghesquieres, MD PhD, Cedric Rossi, MD PhD, Fanny Cherblanc, PhD, Sandra Le Guyader, PhD, Fontanet Bijou, MD, Pierre Sujobert, MD PhD, Pascale Fabbro-Peray, MD PhD, Luc Mathieu Fornecker, MD PhD, Adeline Bernier, PhD, Isabelle Baldi, MD PhD, Krimo Bouabdallah, MD, Camille Laurent, MD PhD, Lucie Oberic, MD, Nadine Morineau, MD, Gilles A. Salles, MD PhD, Loic Ysebaert, MD PhD, Alain Monnereau, MD PhD

Blood (2019) 134 (Supplement_1): 4762.

https://doi.org/10.1182/blood-2019-129204

Published: 2019

Journal Articles

Prognostic Impact of Clonal Diversity in Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy (IC)

Blood (2019) 134 (Supplement_1): 2700.

https://doi.org/10.1182/blood-2019-127475

Published: 2019

Journal Articles

Cannibalistic acute myeloid leukemia with ZMYND11-MBTD1 fusion

Adriana Plesa, Pierre Sujobert

Blood (2019) 133 (16): 1789.

https://doi.org/10.1182/blood-2019-01-898619

Published: 2019

Journal Articles

Stemness Signature in AML: GEP with 17 Genes Score Versus Leukemic Stem Cell (LSC) Quantification By Multiparameter Flow Cytometry (MFC)

Adriana Plesa, Christophe Roumier, PharmD, Florent Dumezy, PharmD, Delphine Manzoni, PharmD, Pierre Sujobert, MD PhD, Sandrine Hayette, Isabelle Tigaud, MD, Claude Preudhomme, Karine Celli-Lebras, CRA, Yves Bertrand, MD, Herve Dombret, Xavier Thomas, MD, Meyling Cheok, BSPharm, PhD

Blood (2018) 132 (Supplement 1): 4009.

https://doi.org/10.1182/blood-2018-99-119857

Published: 2018

NARROW

Deciphering Thrombosis Risk in Vexas Syndrome Patients through Thrombin Generation Assay Andthromboelastography

Genotype-Phenotype Mapping Via Single-Cell Multi-Omics Identifies Therapeutic Vulnerabilities in Vexas Syndrome

Deep Learning Based Blood Abnormalities Detection As a Tool for Vexas Syndrome Screening

BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study

Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas

Therapeutic options in VEXAS syndrome: insights from a retrospective series

A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia

Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

PKR-like Endoplasmic Reticulum Kinase Mediates Apoptosis Induced By Pharmacological AMP-Activated Protein Kinase Activation in Acute Myeloid Leukemia

Integrating ELN Criteria and a 'Knowledge Bank' Approach to Guide Allogeneic Stem Cell Transplantation (SCT) Indication in Younger Adults with Acute Myeloid Leukemia (AML): An Acute Leukemia French Association Study

A French Multicentric Prospective Cohort of 6000 Patients with Integrative Epidemiological, Clinical, Biological and Treatment Data to Improve Knowledge on Outcome of Lymphoma Patients: Pilot Phase Results of the Real World Data in Lymphoma and Survival in Adults (REALYSA) Study

Prognostic Impact of Clonal Diversity in Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy (IC)

Cannibalistic acute myeloid leukemia with ZMYND11-MBTD1 fusion

Stemness Signature in AML: GEP with 17 Genes Score Versus Leukemic Stem Cell (LSC) Quantification By Multiparameter Flow Cytometry (MFC)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only